MCID: SNS001
MIFTS: 58

Sensorineural Hearing Loss

Categories: Ear diseases, Rare diseases

Aliases & Classifications for Sensorineural Hearing Loss

MalaCards integrated aliases for Sensorineural Hearing Loss:

Name: Sensorineural Hearing Loss 12 76 29 6 15 73
Sensory Hearing Loss 12 55 73
Hearing Loss, High-Frequency 44 73
Hearing Loss, Sensorineural 44 40
Hearing Loss, Central 44 73
Perceptive Hearing Loss or Deafness 12
High Frequency Hearing Loss 12
High-Frequency Hearing Loss 12
Hearing Loss High-Frequency 55
Hearing Loss Sensorineural 55
High Frequency Deafness 12
Perceptive Hearing Loss 12
Sensorineural Deafness 12
Deafness Sensorineural 55
Central Hearing Loss 12
Perceptive Deafness 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases


Summaries for Sensorineural Hearing Loss

MalaCards based summary : Sensorineural Hearing Loss, also known as sensory hearing loss, is related to deafness, x-linked 2 and deafness, autosomal dominant 22, and has symptoms including tinnitus An important gene associated with Sensorineural Hearing Loss is MT-TL1 (Mitochondrially Encoded TRNA Leucine 1 (UUA/G)), and among its related pathways/superpathways is Gap junction trafficking. The drugs Cisplatin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and brain, and related phenotypes are hearing/vestibular/ear and nervous system

Wikipedia : 76 Sensorineural hearing loss (SNHL) is a type of hearing loss, or deafness, in which the root cause lies... more...

Related Diseases for Sensorineural Hearing Loss

Diseases in the Sensorineural Hearing Loss family:

Nonsyndromic Hereditary Sensorineural Hearing Loss

Diseases related to Sensorineural Hearing Loss via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 903)
# Related Disease Score Top Affiliating Genes
1 deafness, x-linked 2 33.5 GJB2 GJB6
2 deafness, autosomal dominant 22 33.3 COCH MYH9 MYO7A
3 pendred syndrome 32.9 GJB2 MITF SLC26A4
4 deafness, autosomal recessive 9 32.8 GJB2 OTOF
5 deafness, autosomal dominant 36 32.6 GJB2 SLC26A4 TMC1
6 deafness, autosomal recessive 2 32.6 GJB2 MYO7A OTOF
7 auditory neuropathy, autosomal dominant, 1 32.5 GJB2 OTOF
8 deafness, autosomal recessive 23 32.5 GJB2 GJB6 MYO7A SLC26A4
9 deafness, autosomal recessive 6 32.5 GJB2 MYO7A USH2A
10 deafness, autosomal recessive 7 32.5 GJB2 TMC1
11 deafness, autosomal recessive 28 32.4 GJB2 GJB3
12 deafness, autosomal dominant 6 32.4 COCH GJB2 MITF MYO7A OTOF SLC26A4
13 deafness, autosomal recessive 1a 32.4 GJB2 GJB3 GJB6 OTOF
14 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 32.4 ATP6V1B1 COCH GJB2 GJB3 GJB6 MYO7A
15 deafness, autosomal dominant 48 32.4 MYH9 MYO7A
16 deafness, autosomal dominant 2a 32.4 COCH GJB2 GJB6 KCNQ4 WFS1
17 usher syndrome 32.4 CEP78 GJB2 MYO7A USH2A
18 deafness, autosomal recessive 16 32.3 COCH GJB2 GJB6 MYO7A OTOF SLC26A4
19 deafness, autosomal dominant 13 32.2 COCH GJB2 MYO7A OTOF SLC26A4 USH2A
20 deafness, autosomal recessive 37 32.2 MYH9 MYO7A
21 deafness, autosomal recessive 3 32.0 GJB2 MYO7A
22 knuckle pads, leukonychia, and sensorineural deafness 32.0 GJB2 GJB6
23 usher syndrome, type iiia 31.9 CEP78 MYO7A USH2A
24 usher syndrome, type id 31.8 MYO7A USH2A
25 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 31.8 GJB2 GJB3 MITF
26 congenital cytomegalovirus 31.2 GJB2 GJB6
27 auditory neuropathy spectrum disorder 31.1 MYO7A OTOF
28 deafness, autosomal dominant 24 31.1 GJB2 GJB6
29 deafness, autosomal recessive 26 31.1 GJB2 OTOF SLC26A4
30 deafness, autosomal recessive 59 31.1 GJB2 OTOF
31 deafness, autosomal recessive 85 31.1 MYO7A OTOF SLC26A4
32 deafness, autosomal recessive 83 31.1 MYO7A OTOF SLC26A4
33 autosomal recessive nonsyndromic deafness 31.1 GJB2 OTOF SLC26A4 TMC1
34 deafness, autosomal recessive 30 31.0 GJB2 MYH9 MYO7A SLC26A4 TMC1
35 autosomal recessive nonsyndromic deafness 3 31.0 GJB2 MYH9 MYO7A OTOF SLC26A4
36 hypotrichosis-deafness syndrome 31.0 GJB2 GJB3
37 deafness, autosomal recessive 93 31.0 GJB2 GJB3
38 autosomal dominant nonsyndromic deafness 30.6 COCH GJB2 GJB3 KCNQ4 MYH9 MYO7A
39 knuckle pads 30.6 GJB2 GJB3 GJB6
40 autosomal recessive disease 30.6 ATP6V1B1 CEP78 SLC26A4
41 dfnb1 30.5 GJB2 GJB6 MYO7A OTOF
42 retinitis pigmentosa-deafness syndrome 30.5 MYO7A USH2A
43 non-syndromic genetic deafness 30.5 COCH GJB2 KARS KCNQ4 MYH9 OTOF
44 autosomal recessive non-syndromic sensorineural deafness type dfnb 30.4 GJB2 GJB3 GJB6 KARS MYH9 MYO7A
45 mutism 30.4 GJB2 MITF
46 kid syndrome 30.3 GJB2 GJB3 GJB6
47 clouston syndrome 30.2 GJB2 GJB3 GJB6
48 auditory system disease 29.7 ATP6V1B1 COCH GJB2 GJB3 GJB6 KCNQ4
49 nonsyndromic deafness 29.3 COCH GJB2 GJB3 GJB6 KARS KCNQ4
50 split-hand/foot malformation 1 with sensorineural hearing loss, autosomal recessive 12.8

Comorbidity relations with Sensorineural Hearing Loss via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Hypertension, Essential
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Sensorineural Hearing Loss:



Diseases related to Sensorineural Hearing Loss

Symptoms & Phenotypes for Sensorineural Hearing Loss

UMLS symptoms related to Sensorineural Hearing Loss:


tinnitus

MGI Mouse Phenotypes related to Sensorineural Hearing Loss:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.97 ATP6V1B1 COCH GJB2 GJB6 KCNQ4 LMX1A
2 nervous system MP:0003631 9.73 ATP6V1B1 GJB2 GJB6 KCNQ4 LMX1A MITF
3 no phenotypic analysis MP:0003012 9.28 GJB2 GJB3 GJB6 LMX1A MITF MYH9

Drugs & Therapeutics for Sensorineural Hearing Loss

Drugs for Sensorineural Hearing Loss (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 1,Phase 2 15663-27-1 2767 441203 84093
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
6
protease inhibitors Phase 4,Phase 2,Phase 3
7 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
9 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
10 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
11 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
14 BB 1101 Phase 4,Phase 3,Phase 2,Not Applicable
15 Dexamethasone 21-phosphate Phase 4,Phase 2
16 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
17 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3 53-03-2 5865
20
Valganciclovir Approved, Investigational Phase 3,Phase 2 175865-60-8 64147
21
Ganciclovir Approved, Investigational Phase 3,Phase 2 82410-32-0 3454
22
Acyclovir Approved Phase 2, Phase 3 59277-89-3 2022
23
Iron Approved Phase 2, Phase 3 7439-89-6 23925
24
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
25
Acetylcysteine Approved, Investigational Phase 2, Phase 3,Phase 1 616-91-1 12035
26
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
27
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
28
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
29
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
32
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
33
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
34
Polyestradiol phosphate Approved Phase 3 28014-46-2
35
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
36 Estradiol valerate Approved, Investigational, Vet_approved Phase 3 979-32-8
37
Povidone Approved Phase 3 9003-39-8
38
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
39
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
40
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
41
leucovorin Approved Phase 3 58-05-9 6006 143
42
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
43 Antiviral Agents Phase 3,Phase 2,Phase 1
44 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2,Not Applicable
45 Anti-Infective Agents Phase 3,Phase 2,Phase 1
46 Ganciclovir triphosphate Phase 3,Phase 2
47 Incretins Phase 2, Phase 3
48 Protective Agents Phase 2, Phase 3,Phase 3,Phase 1
49 Antioxidants Phase 2, Phase 3,Phase 1
50 Expectorants Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4 Dexamethasone Phosphate
2 Diaphragmatic Movement Before and After Stellate Ganglion Block : A Ultrasonographic Study Completed NCT01054378 Phase 4
3 Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss Unknown status NCT00416143 Phase 2, Phase 3 prednisone - oral corticosteroid 1mg/kg/D for 1 week
4 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
5 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
6 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
7 Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Unknown status NCT02882477 Phase 2, Phase 3 Deferiprone;Acetylcysteine;Sitagliptin and Metformin
8 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
9 AM-111 in the Treatment of Acute Inner Ear Hearing Loss Completed NCT02561091 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
10 Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss Completed NCT00335920 Phase 3 Dexamethasone-dihydrogenphosphate (4mg/ml)
11 Evaluation of a Binaural Spatialization Method for Hearing Aids Completed NCT02693704 Phase 2, Phase 3
12 Sudden Deafness Treatment Trial Completed NCT00097448 Phase 3 prednisone;methylprednisolone sodium succinate
13 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3 Somatropin;Ethinyl estradiol;Medroxyprogesterone acetate
14 Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Recruiting NCT03374514 Phase 3 Dexamethasone;Sterile isotonic saline solution
15 Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance Recruiting NCT02606266 Phase 2, Phase 3 Valganciclovir
16 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Active, not recruiting NCT01376778 Phase 3 CMV hyperimmune globulin
17 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Enrolling by invitation NCT03107871 Phase 3 Valganciclovir;Simple Syrup
18 Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss Not yet recruiting NCT03603314 Phase 2, Phase 3 SENS-401;SENS-401
19 Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL Not yet recruiting NCT03331627 Phase 3 STR001-IT and STR001-ER
20 Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment Terminated NCT02809118 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
21 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Terminated NCT01655212 Phase 3 Valganciclovir
22 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3 Corticosteroids;Methotrexate
23 Effectiveness of P02 Digital Hearing Aids Unknown status NCT01902914 Phase 1, Phase 2
24 Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity Unknown status NCT01108601 Phase 1, Phase 2 Ringer's Lactate (0.03% Ciprofloxacin)
25 Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss Completed NCT00802425 Phase 2 AM-111;placebo
26 Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss Completed NCT01621256 Phase 1, Phase 2 Ancrod;Saline solution
27 Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss Completed NCT02038972 Phase 1, Phase 2
28 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
29 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
30 Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus Completed NCT00860808 Phase 2 AM-101
31 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease Completed NCT01133860 Phase 2 eltrombopag
32 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
33 High Dose Oral Steroids in Sudden Sensorineural Hearing Loss Recruiting NCT03255473 Phase 2 Dexamethasone;Prednisone
34 Effectiveness of Therapy Via Telemedicine Following Cochlear Implants Recruiting NCT02497690 Phase 2
35 SPI-1005 for the Treatment of Patients With Meniere's Disease Recruiting NCT03325790 Phase 2 200mg SPI-1005 BID;400mg SPI-1005 BID
36 FX-322 in Sensorineural Hearing Loss Active, not recruiting NCT03616223 Phase 1, Phase 2 FX-322;Placebo
37 SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity Enrolling by invitation NCT02819856 Phase 1, Phase 2 Placebo;SPI-1005 Ebselen 200mg Capsule x1;SPI-1005 Ebselen 200mg Capsule x2;SPI-1005 Ebselen 200mg Capsule x3
38 Asymptomatic Congenital CMV Treatment Not yet recruiting NCT03301415 Phase 2 Valganciclovir
39 Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Suspended NCT02616172 Phase 1, Phase 2
40 Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss Terminated NCT02414152 Phase 1, Phase 2 anakinra
41 A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss Completed NCT01518920 Phase 1 PF-04958242;PF-04958242;Placebo
42 Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding Completed NCT00582946 Phase 1
43 Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Completed NCT02259595 Phase 1 HPN-07;NAC;Placebo
44 Middle-Ear Implant With MET V Transducer (Aka MET V System) Unknown status NCT01529333 Not Applicable
45 Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery Unknown status NCT02093806
46 Fludrocortisone for Sudden Hearing Loss Unknown status NCT01186185 Not Applicable Fludrocortisone
47 Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis Unknown status NCT02252601 Not Applicable
48 Cochlear Implant and Vestibular Function. Unknown status NCT02584361 Not Applicable
49 Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old Unknown status NCT00140699
50 Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals Completed NCT00787189 Not Applicable

Search NIH Clinical Center for Sensorineural Hearing Loss

Cochrane evidence based reviews: hearing loss, central

Genetic Tests for Sensorineural Hearing Loss

Genetic tests related to Sensorineural Hearing Loss:

# Genetic test Affiliating Genes
1 Sensorineural Hearing Loss 29

Anatomical Context for Sensorineural Hearing Loss

MalaCards organs/tissues related to Sensorineural Hearing Loss:

41
Bone, Testes, Brain, Neutrophil, Endothelial, Cortex, Pituitary

Publications for Sensorineural Hearing Loss

Articles related to Sensorineural Hearing Loss:

(show top 50) (show all 1946)
# Title Authors Year
1
Prevalence and etiology of sensorineural hearing loss in children with down syndrome: A cross-sectional study. ( 30554691 )
2019
2
Radiographic findings in young adults with asymmetric sensorineural hearing loss. ( 30472122 )
2019
3
Assessment of balance skills and falling risk in children with congenital bilateral profound sensorineural hearing loss. ( 30554713 )
2019
4
Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment. ( 30334605 )
2019
5
Prognostic factors regarding the hearing outcome in severe to profound sudden sensorineural hearing loss treated by tympanotomy and sealing of labyrinthine windows after ineffective systemic corticosteroid application. ( 29855690 )
2018
6
Disruptive Hearing Technologies and Mild Sensorineural Hearing Loss II: Current Research on Affordable Hearing Technologies and Direct-to-Consumer Models. ( 29915452 )
2018
7
Risk factors of sensorineural hearing loss in patients with unilateral safe chronic suppurative otitis media. ( 29331307 )
2018
8
Association of Sudden Sensorineural Hearing Loss With Risk of Cardiocerebrovascular Disease: A Study Using Data From the Korea National Health Insurance Service. ( 29270613 )
2018
9
Which Patients With Asymmetric Sensorineural Hearing Loss Should Undergo Imaging? ( 29392735 )
2018
10
Mobile Hearing Testing Applications and the Diagnosis of Sudden Sensorineural Hearing Loss: A Cautionary Tale. ( 29227445 )
2018
11
Hypertrophic Pachymeningitis of the Internal Auditory Canal: A Rare Case of Unilateral Sudden Sensorineural Hearing Loss. ( 29938521 )
2018
12
Assessment of Spontaneous Recovery Rates in Patients With Idiopathic Sudden Sensorineural Hearing Loss. ( 29931029 )
2018
13
Comparison of intratympanic dexamethasone therapy and hyperbaric oxygen therapy for the salvage treatment of refractory high-frequency sudden sensorineural hearing loss. ( 29891394 )
2018
14
Bony cochlear nerve canal stenosis in pediatric unilateral sensorineural hearing loss. ( 29447896 )
2018
15
Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. ( 29149379 )
2018
16
Utilization of diagnostic testing for pediatric sensorineural hearing loss. ( 29958610 )
2018
17
Oral and intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss. ( 29721537 )
2018
18
Compensated Vestibular Dysfunction Post Cochlear Implantation in Children with Sensorineural Hearing Loss: A Prospective Study. ( 29977841 )
2018
19
The role of explorative tympanotomy in patients with sudden sensorineural hearing loss with and without perilymphatic fistula. ( 29055686 )
2018
20
Fever of unknown origin, bilateral sensorineural hearing loss with canal paresis and uveitis with iridocyclitis and episcleritis: a case of Cogan's syndrome. ( 29703835 )
2018
21
A protocol for a network meta-analysis of interventions to treat patients with sudden sensorineural hearing loss. ( 29769117 )
2018
22
Delayed Recovery in Pediatric Sudden Sensorineural Hearing Loss Predicted via Magnetic Resonance Imaging. ( 29717656 )
2018
23
Unilateral Sensorineural Hearing Loss Presenting With Bilateral Temporal Bone Lesions. ( 29342040 )
2018
24
Inpatient treatment of patients with idiopathic sudden sensorineural hearing loss: a population-based healthcare research study. ( 29330597 )
2018
25
Association of Vertigo With Hearing Outcomes in Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. ( 29931169 )
2018
26
Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study. ( 29965935 )
2018
27
Idiopathic Sudden Sensorineural Hearing Loss Is Not a Sentinel Event for Acute Myocardial Infarction. ( 29912831 )
2018
28
Prognostic role of haematological indices in sudden sensorineural hearing loss: Review and meta-analysis. ( 29684383 )
2018
29
Can A Sudden Sensorineural Hearing Loss Occur Due to Miliary Tuberculosis? ( 29036759 )
2018
30
Comparison of 2 and 4 Intratympanic Steroid Injections in the Treatment of Idiopathic Sudden Sensorineural Hearing Loss. ( 29411622 )
2018
31
Association of Idiopathic Sudden Sensorineural Hearing Loss With Affective Disorders. ( 29852049 )
2018
32
The Clinical Value of Vertigo as a Prognostic Indicator of Outcome in Sudden Sensorineural Hearing Loss. ( 29931206 )
2018
33
Mobile phone usage does not affect sudden sensorineural hearing loss. ( 29179790 )
2018
34
Association of Metabolic Syndrome With Sudden Sensorineural Hearing Loss. ( 29450496 )
2018
35
Benefits from, Satisfaction with, and Self-Efficacy for Advanced Digital Hearing Aids in Users with Mild Sensorineural Hearing Loss. ( 29915453 )
2018
36
Coexistence of IL-6 -572C/G and ICAM-1 K469E Polymorphisms among Patients with Sudden Sensorineural Hearing Loss. ( 29695657 )
2018
37
The Characteristic and Short-Term Prognosis of Tinnitus Associated with Sudden Sensorineural Hearing Loss. ( 29861716 )
2018
38
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
39
TMTC2 variant associated with sensorineural hearing loss and auditory neuropathy spectrum disorder in a family dyad. ( 29671961 )
2018
40
Modified Siegel's criteria for sudden sensorineural hearing loss: Reporting recovery outcomes with matched pretreatment hearing grades. ( 29929833 )
2018
41
Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection. ( 29441223 )
2018
42
Contralateral sensorineural hearing loss after vestibular schwannoma surgery. ( 29929725 )
2018
43
Low-Frequency Sensorineural Hearing Loss in Familial Hemophagocytic Lymphohistiocytosis Type 5. ( 29776323 )
2018
44
Effect of Antioxidant Vitamins as Adjuvant Therapy for Sudden Sensorineural Hearing Loss: Systematic Review Study. ( 29929192 )
2018
45
Prevalence of otitis media and risk-factors for sensorineural hearing loss among infants attending Child Welfare Clinics in the Solomon Islands. ( 29958609 )
2018
46
Sudden Sensorineural Hearing Loss in the Department of Defense. ( 29631507 )
2018
47
Hearing Aids as a Treatment for Tinnitus Patients with Slight to Mild Sensorineural Hearing Loss. ( 29915450 )
2018
48
Disruptive Hearing Technologies and Mild Sensorineural Hearing Loss I: Accessibility and Affordability Issues. ( 29915451 )
2018
49
B3GALNT2-Related Dystroglycanopathy: Expansion of the Phenotype with Novel Mutation Associated with Muscle-Eye-Brain Disease, Walker-Warburg Syndrome, Epileptic Encephalopathy-West Syndrome, and Sensorineural Hearing Loss. ( 29791932 )
2018
50
Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. ( 29470486 )
2018

Variations for Sensorineural Hearing Loss

ClinVar genetic disease variations for Sensorineural Hearing Loss:

6 (show all 24)
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 NC_012920.1: m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh37 Chromosome MT, 3243: 3243
2 MT-TL1 NC_012920.1: m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh38 Chromosome MT, 3243: 3243
3 MT-CYB NC_012920.1: m.15127C> T single nucleotide variant Uncertain significance rs1057516074 GRCh37 Chromosome MT, 15127: 15127
4 MT-CYB NC_012920.1: m.15127C> T single nucleotide variant Uncertain significance rs1057516074 GRCh38 Chromosome MT, 15127: 15127
5 COL11A2 NM_080680.2(COL11A2): c.4430G> T (p.Gly1477Val) single nucleotide variant Likely pathogenic rs745434198 GRCh37 Chromosome 6, 33133760: 33133760
6 COL11A2 NM_080680.2(COL11A2): c.4430G> T (p.Gly1477Val) single nucleotide variant Likely pathogenic rs745434198 GRCh38 Chromosome 6, 33165983: 33165983
7 MYH14 NM_001145809.1(MYH14): c.1945+6G> A single nucleotide variant Uncertain significance rs1057518869 GRCh37 Chromosome 19, 50756016: 50756016
8 MYH14 NM_001145809.1(MYH14): c.1945+6G> A single nucleotide variant Uncertain significance rs1057518869 GRCh38 Chromosome 19, 50252759: 50252759
9 AIFM1 NM_004208.3(AIFM1): c.1019T> C (p.Met340Thr) single nucleotide variant Likely pathogenic rs1057518895 GRCh38 Chromosome X, 130137134: 130137134
10 AIFM1 NM_004208.3(AIFM1): c.1019T> C (p.Met340Thr) single nucleotide variant Likely pathogenic rs1057518895 GRCh37 Chromosome X, 129271109: 129271109
11 TECTA NM_005422.2(TECTA): c.3107G> A (p.Cys1036Tyr) single nucleotide variant Likely pathogenic rs772606235 GRCh38 Chromosome 11, 121137586: 121137586
12 TECTA NM_005422.2(TECTA): c.3107G> A (p.Cys1036Tyr) single nucleotide variant Likely pathogenic rs772606235 GRCh37 Chromosome 11, 121008295: 121008295
13 LMX1A NM_001174069.1(LMX1A): c.1106T> C (p.Ile369Thr) single nucleotide variant Pathogenic rs763320093 GRCh37 Chromosome 1, 165173160: 165173160
14 LMX1A NM_001174069.1(LMX1A): c.1106T> C (p.Ile369Thr) single nucleotide variant Pathogenic rs763320093 GRCh38 Chromosome 1, 165203923: 165203923
15 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh37 Chromosome 1, 151378740: 151378740
16 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh38 Chromosome 1, 151406264: 151406264
17 ESPN NM_031475.2(ESPN): c.2150A> G (p.Asn717Ser) single nucleotide variant Uncertain significance rs921702586 GRCh37 Chromosome 1, 6511981: 6511981
18 ESPN NM_031475.2(ESPN): c.2150A> G (p.Asn717Ser) single nucleotide variant Uncertain significance rs921702586 GRCh38 Chromosome 1, 6451921: 6451921
19 GSDME NM_001127453.1(GSDME): c.456T> G (p.Asn152Lys) single nucleotide variant Uncertain significance rs148449230 GRCh38 Chromosome 7, 24719167: 24719167
20 GSDME NM_001127453.1(GSDME): c.456T> G (p.Asn152Lys) single nucleotide variant Uncertain significance rs148449230 GRCh37 Chromosome 7, 24758786: 24758786
21 KARS NM_001130089.1(KARS): c.1438del (p.Leu480Trpfs) deletion Pathogenic GRCh37 Chromosome 16, 75664391: 75664391
22 KARS NM_001130089.1(KARS): c.1438del (p.Leu480Trpfs) deletion Pathogenic GRCh38 Chromosome 16, 75630493: 75630493
23 GJB2 NM_004004.5(GJB2): c.196G> T (p.Asp66Tyr) single nucleotide variant Likely pathogenic rs104894403 GRCh37 Chromosome 13, 20763525: 20763525
24 GJB2 NM_004004.5(GJB2): c.196G> T (p.Asp66Tyr) single nucleotide variant Likely pathogenic rs104894403 GRCh38 Chromosome 13, 20189386: 20189386

Copy number variations for Sensorineural Hearing Loss from CNVD:

7 (show all 13)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 115500 17 58121080 60118579 Deletion Sensorineural hearing loss
2 115503 17 58121080 60118579 Deletion APPBP2 sensorineural hearing loss
3 115507 17 58121080 60118579 Deletion BCAS3 sensorineural hearing loss
4 115511 17 58121080 60118579 Deletion BRIP1 sensorineural hearing loss
5 115515 17 58121080 60118579 Deletion CA4 sensorineural hearing loss
6 115519 17 58121080 60118579 Deletion INTS2 sensorineural hearing loss
7 115523 17 58121080 60118579 Deletion MED13 sensorineural hearing loss
8 115527 17 58121080 60118579 Deletion NACA2 sensorineural hearing loss
9 115531 17 58121080 60118579 Deletion PPM1D sensorineural hearing loss
10 115535 17 58121080 60118579 Deletion TBX2 sensorineural hearing loss
11 115539 17 58121080 60118579 Deletion TBX4 sensorineural hearing loss
12 115543 17 58121080 60118579 Deletion USP32 sensorineural hearing loss
13 115552 17 58172730 60315273 Deletion Sensorineural hearing loss

Expression for Sensorineural Hearing Loss

Search GEO for disease gene expression data for Sensorineural Hearing Loss.

Pathways for Sensorineural Hearing Loss

Pathways related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.79 GJB2 GJB3 GJB6

GO Terms for Sensorineural Hearing Loss

Cellular components related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.55 ATP6V1B1 GJB6 MYO7A SLC26A4 USH2A
2 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
3 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inner ear morphogenesis GO:0042472 9.54 ATP6V1B1 KCNQ4 MYO7A
2 calcium ion homeostasis GO:0055074 9.48 ATP6V1B1 WFS1
3 actin filament-based movement GO:0030048 9.46 MYH9 MYO7A
4 regulation of pH GO:0006885 9.43 ATP6V1B1 SLC26A4
5 sensory perception of light stimulus GO:0050953 9.4 MYO7A USH2A
6 sensory perception of sound GO:0007605 9.4 ATP6V1B1 COCH GJB2 GJB6 KCNQ4 MYO7A
7 inner ear development GO:0048839 9.33 GJB2 GJB6 MYO7A
8 inner ear receptor cell differentiation GO:0060113 9.32 MYO7A USH2A
9 olfactory behavior GO:0042048 9.26 LMX1A WFS1
10 cell communication GO:0007154 9.13 GJB2 GJB3 GJB6

Molecular functions related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microfilament motor activity GO:0000146 9.26 MYH9 MYO7A
2 gap junction channel activity GO:0005243 9.16 GJB2 GJB3
3 actin-dependent ATPase activity GO:0030898 8.96 MYH9 MYO7A
4 calmodulin binding GO:0005516 8.92 KCNQ4 MYH9 MYO7A WFS1

Sources for Sensorineural Hearing Loss

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....